Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26348504 | 0.90 | AKT1 (0.45) | AKT1OPRD1RENALDH1A1SMN1; SMN2 | |
| SCHEMBL25877236 | 0.88 | AKT1 (0.44) | AKT1OPRD1RENPSMB5OPRM1 | |
| SCHEMBL25877071 | 0.88 | AKT1 (0.44) | AKT1OPRD1RENPSMB5OPRM1 | |
| SCHEMBL25877257 | 0.88 | AKT1 (0.44) | AKT1OPRD1RENPSMB5OPRM1 | |
| SCHEMBL26503041 | 0.88 | AKT1 (0.47) | AKT1OPRD1RENALDH1A1SMN1; SMN2 | |
| SCHEMBL26348473 | 0.87 | AKT1 (0.40) | AKT1OPRD1RENHRH1PSMB5 | |
| SCHEMBL26678546 | 0.87 | AKT1 (0.42) | AKT1OPRD1ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL26027305 | 0.87 | AKT1 (0.42) | AKT1OPRD1ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL26027432 | 0.87 | AKT1 (0.42) | AKT1OPRD1ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL22479733 | 0.84 | AKT1 (0.48) | AKT1OPRD1ALDH1A1SMN1; SMN2PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | GLP1R, ADGRF1, CCKAR | AKT1 1605/4885OPRD1 1381/4885REN 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.